Accuray Incorporated (ARAY) Shares Bought by Global X Management Co. LLC

Global X Management Co. LLC increased its stake in Accuray Incorporated (NASDAQ:ARAY) by 126.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 887,287 shares of the medical equipment provider’s stock after purchasing an additional 495,272 shares during the quarter. Global X Management Co. LLC owned about 1.04% of Accuray worth $3,815,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the stock. Wells Fargo & Company MN lifted its holdings in Accuray by 1.5% in the second quarter. Wells Fargo & Company MN now owns 62,059 shares of the medical equipment provider’s stock worth $295,000 after purchasing an additional 936 shares during the period. The Manufacturers Life Insurance Company lifted its holdings in Accuray by 5.0% in the second quarter. The Manufacturers Life Insurance Company now owns 67,565 shares of the medical equipment provider’s stock worth $320,000 after purchasing an additional 3,246 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in Accuray by 1.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 413,032 shares of the medical equipment provider’s stock worth $1,962,000 after purchasing an additional 4,812 shares during the period. Voya Investment Management LLC lifted its holdings in Accuray by 16.4% in the second quarter. Voya Investment Management LLC now owns 44,373 shares of the medical equipment provider’s stock worth $211,000 after purchasing an additional 6,262 shares during the period. Finally, AHL Partners LLP lifted its holdings in Accuray by 28.4% in the second quarter. AHL Partners LLP now owns 39,823 shares of the medical equipment provider’s stock worth $189,000 after purchasing an additional 8,817 shares during the period. 80.49% of the stock is owned by institutional investors and hedge funds.

In other Accuray news, CFO Kevin Waters sold 7,154 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $5.06, for a total value of $36,199.24. Following the completion of the sale, the chief financial officer now directly owns 335,087 shares of the company’s stock, valued at approximately $1,695,540.22. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Joshua Levine sold 17,093 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $4.86, for a total transaction of $83,071.98. Following the completion of the sale, the chief executive officer now directly owns 1,435,428 shares of the company’s stock, valued at $6,976,180.08. The disclosure for this sale can be found here. Insiders sold a total of 26,413 shares of company stock valued at $129,798 over the last three months. 3.90% of the stock is owned by corporate insiders.

Shares of Accuray Incorporated (NASDAQ:ARAY) opened at $5.25 on Friday. Accuray Incorporated has a 1-year low of $3.60 and a 1-year high of $6.15. The company has a debt-to-equity ratio of 2.66, a current ratio of 1.54 and a quick ratio of 0.99. The firm has a market cap of $447.79, a PE ratio of -18.10 and a beta of 1.77.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings results on Tuesday, January 23rd. The medical equipment provider reported ($0.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.11) by $0.05. Accuray had a negative net margin of 6.09% and a negative return on equity of 44.66%. The company had revenue of $100.33 million during the quarter, compared to the consensus estimate of $90.31 million. During the same period in the prior year, the company earned ($0.11) EPS. Accuray’s revenue was up 14.7% on a year-over-year basis. equities research analysts anticipate that Accuray Incorporated will post -0.19 earnings per share for the current fiscal year.

Several research firms recently weighed in on ARAY. Zacks Investment Research raised shares of Accuray from a “hold” rating to a “buy” rating and set a $5.75 price objective for the company in a report on Tuesday. BidaskClub downgraded shares of Accuray from a “buy” rating to a “hold” rating in a report on Thursday, February 8th. Royal Bank of Canada set a $6.00 price objective on shares of Accuray and gave the stock a “hold” rating in a report on Wednesday, January 24th. Lake Street Capital began coverage on shares of Accuray in a report on Thursday, November 30th. They issued a “buy” rating and a $10.00 price objective for the company. Finally, JPMorgan Chase & Co. downgraded shares of Accuray from a “neutral” rating to an “underweight” rating and set a $6.00 price objective for the company. in a report on Wednesday, December 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $7.13.

ILLEGAL ACTIVITY WARNING: This news story was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.dispatchtribunal.com/2018/02/17/accuray-incorporated-aray-shares-bought-by-global-x-management-co-llc.html.

About Accuray

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.

Want to see what other hedge funds are holding ARAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accuray Incorporated (NASDAQ:ARAY).

Institutional Ownership by Quarter for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply